PRESSEPORTAL Presseportal Logo
All Stories
Follow
Subscribe to Stada Arzneimittel

07.08.2020 – 13:33

Stada Arzneimittel

Press Release: Nidda Healthcare GmbH sets cash compensation for the transfer of the shares of the minority shareholders of STADA Arzneimittel AG at 98.51 EUR

One document

Nidda Healthcare GmbH sets cash compensation for the transfer of the shares of the minority shareholders of STADA Arzneimittel AG at 98.51 EUR

Bad Vilbel, August 7, 2020 - Nidda Healthcare GmbH (Nidda), today reconfirmed to the management board of STADA Arzneimittel AG (STADA) its formal request from June 5 to transfer all shares of STADA's minority shareholders to Nidda and repeated the request providing further details. Nidda has asked that STADA convene an extraordinary general meeting at short notice to resolve on the transfer of the shares of STADA's minority shareholders to Nidda as the main shareholder in return for an adequate cash compensation. The cash compensation to be paid as consideration for the transfer of the shares has been determined by Nidda at 98.51 Euro per STADA share. The amount of the cash compensation will be reviewed by a court-appointed expert auditor to confirm the appropriateness of the cash compensation.

The Extraordinary General Meeting of STADA is expected to take place on September 24, 2020.

About STADA Arzneimittel AG

STADA Arzneimittel AG is headquartered in Bad Vilbel, Germany. The company focuses on a two-pillar strategy consisting of generics, including specialty pharmaceuticals and non-prescription consumer health products. Worldwide, STADA Arzneimittel AG sells its products in approximately 120 countries. In financial year 2019, STADA achieved adjusted Group sales of EUR 2,608.6 million and adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of EUR 625.5 million. As of December 31, 2019, STADA employed 11,100 people worldwide.

Additional information for journalists:

STADA Arzneimittel AG
Media Relations
Stadastrasse 2-18
61118 Bad Vilbel - Germany 
Phone: +49 (0) 6101 603-165
Fax: +49 (0) 6101 603-215
E-Mail: press@stada.de
Or visit us on the Internet at www.stada.com/press

Additional information for capital market participants:

STADA Arzneimittel AG
Investor & Creditor Relations
Stadastrasse 2-18
61118 Bad Vilbel - Germany'
Phone: +49 (0) 6101 603-4689
Fax: +49 (0) 6101 603-215
E-mail: ir@stada.de

Or visit us on the Internet at www.stada.com/investor-relations